

## Short Original

# Total renal volume and renal function after radical nephrectomy in renal neoplasm<sup>☆</sup>

Saúl Pampa-Saico<sup>a,b,\*</sup>, Simona Alexandru<sup>a,b</sup>, M. Soledad Pizarro-Sánchez<sup>a,b</sup>,  
María López-Picasso<sup>a,b</sup>, Laura García Puente-Suárez<sup>a,b</sup>, Raquel Barba<sup>a,b</sup>,  
Fernando Liaño<sup>c</sup>

<sup>a</sup> Departamento de Nefrología, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain

<sup>b</sup> Universidad Rey Juan Carlos, Móstoles, Madrid, Spain

<sup>c</sup> Instituto Ramón y Cajal de Investigación Sanitaria (IRyCis), Hospital Universitario Ramón y Cajal, Madrid, Spain

## ARTICLE INFO

## Article history:

Received 13 February 2020

Accepted 18 October 2020

## Keywords:

Radical nephrectomy

Renal neoplasm

Total renal volume

## ABSTRACT

**Introduction:** The reduction of renal mass after radical nephrectomy (RN) for renal neoplasm, could be associated with compensatory hypertrophy of the contralateral kidney. The capacity of compensation will determine the renal function (RF) evolution. Measuring of total renal volume (TRV) of the remaining kidney pre and post RN can help assess the RF evolution.

**Objectives:** To determine the correlation between TRV pre and post nephrectomy (a year of follow-up) with RF.

**Materials and methods:** A retrospective cohort study was carried out in 47 patients who had undergone RN from 2014 to 2018, due to renal cell carcinoma (confirmed by histopathology).

The TRV was calculated, pre and post (a year of follow-up) RN, using ellipsoid formula equation, which were compared with clinical and analytical data. The results were analyzed by multivariate linear logistic models.

**Results:** The median age at the time of RN was 70 years old (range, 40–88 years). Most of them were men, 66%. The estimated glomerular filtration rate (eGFR) pre and post nephrectomy was 78 (40–100) and 53.3 ml/min/m<sup>2</sup> (30–90) respectively ( $p=0.01$ ). The TRV pre and post-nephrectomy was 168.2 ml (100.4–257.2) and 187.8 ml (115.5–273.1) respectively ( $p=0.001$ ).

The pre-nephrectomy eGFR ( $\beta=0.62$ ;  $p=0.034$ ) and the TRV ( $\beta=1.08$ ;  $p<0.0001$ ) were positively correlated with the post-nephrectomy TRV, while the eGFR at year of follow-up was correlated negatively ( $\beta=-1.18$ ;  $p=0.047$ ).

**Conclusions:** The measurement of pre and post nephrectomy TRV can help to predict renal function evolution at a year of follow-up.

© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article:

<https://doi.org/10.1016/j.nefro.2020.10.009>.

<sup>☆</sup> Please cite this article as: Pampa-Saico S, Alexandru S, Pizarro-Sánchez MS, López-Picasso M, Puente-Suárez LG, Barba R, et al. Volumen renal total y función renal en pacientes nefrectomizados por neoplasias renales. Nefrología. 2021;41:446–452.

\* Corresponding author.

E-mail address: [saups5@hotmail.com](mailto:saups5@hotmail.com) (S. Pampa-Saico).

2013-2514/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Volumen renal total y función renal en pacientes nefrectomizados por neoplasias renales

### R E S U M E N

#### Palabras clave:

Nefrectomía radical  
Neoplasias renales  
Volumen renal total

**Introducción:** La reducción de la masa renal tras la nefrectomía radical en pacientes con neoplasias renales puede producir la hipertrofia compensadora del riñón contralateral. La capacidad de compensación determinará la evolución de la función renal. La medición del volumen renal total (VRT) del riñón remanente antes y después de la nefrectomía puede ayudar a evaluar la evolución de la función renal.

**Objetivos:** Determinar la correlación entre el VRT pre y posnefrectomía con la función renal al año de seguimiento.

**Materiales y métodos:** Estudio retrospectivo de observación en 47 pacientes adultos con neoplasias renales que fueron sometidos a nefrectomía radical. El VRT pre y posnefrectomía (al año de seguimiento) fue calculado mediante la ecuación de la elipsoide (TAC y/o RNM), que fueron comparados con datos clínicos y analíticos. Los resultados fueron analizados mediante regresión lineal uni y multivariante.

**Resultados:** La mediana de edad al momento de la nefrectomía fue de 70 años (44-88). La mayoría fueron hombres (66%). El filtrado glomerular estimado (FGe) pre y posnefrectomía fue de 78 (40-100) y 53,3 ml/min/m<sup>2</sup> (20-90) respectivamente ( $p = 0,01$ ). El VRT pre y posnefrectomía fue de 168,2 ml (100,4-257,2) y 187,8 ml (115,5-273,1) respectivamente ( $p = 0,001$ ).

El FGe prenefrectomía ( $\beta = 0,62$ ;  $p = 0,034$ ) y el VRT pre ( $\beta = 1,08$ ;  $p < 0,0001$ ) se correlacionaron positivamente con el VRT posnefrectomía. Sin embargo, el FGe al año se correlacionó negativamente ( $\beta = -1,18$ ;  $p = 0,047$ ).

**Conclusiones:** En pacientes con neoplasias renales tratados con nefrectomía radical la medición del VRT pre y posnefrectomía pueden ayudar a predecir la evolución de la función renal al año de seguimiento.

© 2021 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

In recent years there has been an increase in the incidence of kidney neoplasms. Clear cell carcinoma is one of the most frequent, with a prevalence close to 3% of adult malignancies.<sup>1</sup> In clinical practice this represents an important cause of acute renal failure and/or development of chronic kidney disease,<sup>2-4</sup> therefore the nephrologist has a relevant and decisive role in the care, management and follow-up of the evolution of kidney function.

After radical nephrectomy it has been reported that a 33% of this patients develop of acute kidney failure (AKF) and have a 4 times greater risk of developing chronic kidney disease (CKD),<sup>5-7</sup> the risk is lower in patients undergoing partial nephrectomies.<sup>8-11</sup>

Immediately after radical nephrectomy, different compensatory mechanisms are initiated on the remaining kidney to minimize the decrease in glomerular filtration rate.

Measurement of total renal volume (TRV) using the ellipsoid equation is tool widely used in polycystic kidney disease, being the main predictor of the evolution and prognosis of renal function (RF).<sup>12,13</sup>

The measurement of the TRV of the remnant kidney before and after radical nephrectomy (after one year of follow-up) in patients with renal neoplasms has not been fully investigated, and certainly it could help to evaluate the evolution of renal

function and identify the factors that may affect the change in renal function.

The objective of this study was to determine the pre and post-nephrectomy TRV in the remaining kidney and its correlation with the estimated glomerular filtration rate (eGFR) at one year of follow-up.

## Materials and methods

Observational, retrospective study in a court of adult patients ( $\geq 18$  years) seen in the nephrology consultations of the Rey Juan Carlos de Móstoles Hospital, during the period between January 2014 and December 2018.

The study population included all patients identified in our center's database who underwent radical nephrectomy due to renal neoplasm, clear cell carcinoma confirmed by histological analysis. All patients were reevaluated one year after nephrectomy.

Exclusion criteria included: radical nephrectomies for other causes and partial nephrectomies. Those who did not have computerized axial tomography (CT) and/or magnetic resonance imaging (MRI) during follow-up were also excluded.

Demographic, clinical and biochemical parameters were collected in all cases. This information was obtained from the electronic medical records of our institution which included the comorbidities at the time of the nephrectomy (diabetes,

peripheral vascular disease, chronic kidney disease, Charlson comorbidity index).<sup>14</sup>

Serum creatinine (Cr), eGFR and quantification of proteinuria were recorded, pre-nephrectomy (up to 2 months before nephrectomy), at hospital discharge and at one year of follow-up.

Renal function was assessed by calculating the eGFR using the abbreviated formula MDRD-4.<sup>15</sup> The laboratory measurements were carried out in the same hospital by conventional methods.

Total renal volume (TRV) was calculated by using the ellipsoid formula in kidney image obtained by CT and/or MRI. The TRV was obtained before nephrectomy (up to 3 months pre-nephrectomy) and at one year of follow-up.

Calculation of the TRV (ellipsoid equation) =  $\pi/6 \times \text{length} \times \text{width} \times \text{thickness}$ .

To avoid information and selection bias The TRV measurement was carried out by one of the authors who did not have access to clinical or analytical data of the patients. The results of the TRV were compared with the variables of the pre-nephrectomy study and during follow-up.

The study was done in accordance with the principles of the Declaration of Helsinki. Given the minimal risk nature of the study, we were granted a waiver of informed consent.

## Definitions

ARF was defined according to the *Kidney Disease Improving Global Outcomes (KDIGO)*<sup>16</sup> classification. An increase in serum Cr concentration greater than 0.3 mg/dl from baseline produced in less than 48 h, or a 50% increase in baseline serum Cr during the first 7 days after nephrectomy.

CKD was defined as an eGFR less than 60 ml/min/1.73 m<sup>2</sup> for at least 3 months. The eGFR was calculated using the abbreviated formula MDRD-4.<sup>15</sup>

## Study design and statistical methods

Data are presented as mean and standard deviation ( $\pm$ SD), or as median and interquartile ranges (IQR). To compare discrete variables we use the Chi-square test (or Fisher's exact). Student's "t" test for independent samples, or the non-parametric Mann-Whitney test was used to compare 2 continuous variables.

The analysis of the variables that are best associated with TRV and renal function at one year of follow-up, we performed univariate and multivariate linear regression models, adjusting the relevant covariates. A  $p < 0.05$  was considered statistically significant. Statistical analysis was performed with the IBM SPSS version 21 program (IBM Corp. Armonk, USA).

## Results

The study group included 47 patients according to the flow chart shown in Fig. 1.

Table 1 shows the main characteristics of the patients included in the study.

**Table 1 – characteristics of the study group (pre-nephrectomy).**

	Total
Number of patients	47
Age at the time of nephrectomy, years	70 (44–88)
Sex, male/female (%)	31/16 (66/34)
Charlson index	6 (3–9)
Body mass index	28 (21–51)
Smoking, n (%)	31 (66)
HTN, n (%)	29 (61.7)
Diabetes mellitus, n (%)	14 (30)
Obesity, n (%)	15 (32)
Hx of Cardiovascular disease, n (%)	9 (19)
Baseline serum creatinine, mg/dl	0.9 (0.6–1.8)
eGFR, ml/min/1.73 m <sup>2</sup>	78 (40–100)
Previous CKD, n%	4 (8.5)
Proteinuria, n%	2 (4.2)
Kidney size, cm	6.6 (2.2–8.8)
Use of ACEI/ARB-2, n%	27 (61.3)

ARA2: angiotensin 2 receptor antagonists; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ACEI: angiotensin converting enzyme inhibitors; IQR: interquartile range.

Data are presented as median (interquartile range), unless otherwise specified.

A 66% of the patients were men (31/16), with a median age of 70 years (range: 44–88). The diameter of the tumor was 6.6 cm (range: 2.2–8.8). Left nephrectomy was performed in 51% of patients (24/23). Pre-nephrectomy Crs and eGFR were 0.9 mg/dl (0.6–1.8) and 78 ml/min/1.73 m<sup>2</sup> (40–100) respectively. The pre-nephrectomy TRV was 168.2 ml (100.4–257.2) (Table 2).

Thirty-five patients (70.6%) met criteria of ARF after nephrectomy, the majority AKIN 1 (77% [27/35]). Of the 4 patients who had chronic kidney disease at the time of nephrectomy, only one developed ARF.


During the follow-up period, 6 patients (13%) received adjuvant therapy (antiangiogenic drugs: pazopanib [3], axitinib [1]; immunotherapy with nivolumab [2]).

Table 2 shows the evolution of pre-nephrectomy quantitative variables and the values at one year of follow up. The eGFR decreased significantly from 78 (range 40–100) to 53.3 ml/min/1.73 m<sup>2</sup> (range, 20–90) ( $p = 0.01$ ), this was associated with an increase in serum Cr from 0.97 (0.6–1.7) to 1.3 mg/dl (0.7–1.9) ( $p = 0.001$ ). The pre-nephrectomy TRV increased significantly after one year of follow-up, from 168.2 ml (100.4–257.2) to 187.8 ml (115.5–273.1) ( $p = 0.001$ ).

No significant differences were observed in the body mass index after one year of follow-up.

Table 3 shows the results of univariate and multivariate linear regression. The results are the best equation that determine the total renal volume after one year of follow-up. It was found a positive correlation with eGFR pre-nephrectomy ( $\beta = 0.62$ ;  $p = 0.034$ ) and TRV pre-nephrectomy ( $\beta = 1.08$ ;  $p < 0.0001$ ), while with eGFR at one year the correlation was negative ( $\beta = -1.18$ ;  $p = 0.047$ ).

Table 4 shows the multivariate linear regression analysis of variables that influenced the eGFR at one year of follow-up. A positive correlation was observed with respect to the pre-nephrectomy TRV ( $\beta = 0.114$ ;  $p = 0.028$ ) and negative with the TRV after one year of follow up ( $\beta = -360$ ;  $p = 0.002$ ).



**Fig. 1 – Flowchart of the study population.**

**Table 2 – Quantitative variables at the time of nephrectomy and at one year of follow-up.**

Variable	Pre-nephrectomy	Postnephrectomy (year of follow-up)	p value
TRV, ml (IQR) <sup>a</sup>	168.2 (100.4–257.2)	187.8 (115.5–273.1)	0.001
Serum creatinine, mg/dl (IQR) <sup>a</sup>	0.97 (0.6–1.7)	1.3 (0.7–1.9)	0.001
EGFR, ml/min/1.73 m <sup>2</sup> (IQR) <sup>a</sup>	78 (40–100)	53.3 (20–90)	0.01
BMI (IQR) <sup>a</sup>	28 (21–51)	28.4 (21–47)	0.05
Proteinuria, mg/day (IQR) <sup>a</sup>	22.6 (0–132)	60 (0–1000)	0.001
HTN	29	32	0.039

eGFR: estimated glomerular filtration rate; BMI: body mass index; IQR: interquartile range; TRV: total renal volume.

<sup>a</sup> Median and interquartile ranges.

**Table 3 – Variables that influenced the total renal volume at one year of follow-up (univariate and multivariate linear regression analysis).**

Variables	Univariate analysis		Multivariate analysis	
	$\beta$ Coefficient (95% CI)	p value	$\beta$ Coefficient (95% CI)	p value
Age, years	–1.11 (–2.77, 0.55)	0.187	–0.54 (–1.29, 0.21)	0.145
Sex, man	–35.91 (–72.15; 0.31)	0.052	4.52 (–13.13; 22.17)	0.587
Charlson comorbidity index	6.54 (–5.37, 18.46)	0.270		
Smoker	8.82 (–33.10, 50.75)	0.669		
BMI pre-nephrectomy	1.84 (–2.16, 5.85)	0.351		
BMI at one year of follow-up	2.13 (–2.06, 6.33)	0.304		
Size of kidney tumor	–1.02 (–10.46, 0.84)	0.822		
HTN	35.06 (–0.64, 69.48)	0.046	–1.99 (–22.85, 18.86)	0.534
Pre-nephrectomy TRV, ml	0.955 (0.78, 1.13)	0.0001	1.086 (1.034–1.238)	<0.0001
Pre-nephrectomy eGFR (ml/min/1.73 m <sup>2</sup> )	–0.598 (–1.595; 0.066)	0.069	0.627 (0.052–1.202)	0.034
eGFR at hospital discharge	0.683 (–1.57, 2.93)	0.180		
eGFR at one year of follow-up	–0.765 (–1.59; 0.06)	0.086	–1.188 (–1.18; –0.09)	0.047
Pre-nephrectomy proteinuria, mg/dl	0.889 (–0.67, 0.24)	0.252		
Proteinuria at one year of follow-up	0.271 (–0.44, 0.67)	0.672		

R<sup>2</sup> (corrected): 0.865.

eGFR: estimated glomerular filtration rate; CI: confidence interval; BMI: body mass index; TRV: total renal volume.

**Table 4 – Independent factors associated with estimated glomerular filtration rate at one year of follow-up (multivariate linear regression model).**

Variable	$\beta$ Coefficient (95% CI)	p value
Age, years	−0.021 (−5.28, 0.48)	0.93
Pre-nephrectomy eGFR	0.338 (−0.21, 0.69)	0.063
BMI at one year of follow up	−0.652 (−1.35; 0.05)	0.068
TRV pre-nephrectomy	0.114 (0.013, 0.215)	0.028
Post-nephrectomy TRV	−0.360 (−0.56; −0.15)	0.002

Variables that did not enter in the best prediction equation: Charlson comorbidity index ( $p < 0.10$ ), albumin, proteinuria at one year of follow-up, tumor size, ACEI-ARA-2 ( $p = 0.2$ ).  
 $R^2$  corrected: 0.687.  
 eGFR: estimated glomerular filtration rate; BMI: body mass index; TRV: total renal volume.

At one year of follow-up, 60% of the patients (28/47) had developed CKD; the most frequent was CKD stage 3A (70% [20/28]). No patient required renal replacement therapy in the postoperative period or at one year of follow-up. Regarding the use of ACE inhibitors and ARB-2 after nephrectomy, treatment was temporarily suspended in 26% of the patients (9/35) who developed ARF, at the end of the study and a 92% of these patients continued on treatment with ACEI/ARA-2.

## Discussion

The results of this study show that there is a positive correlation between pre and post-nephrectomy TRV and the pre-nephrectomy eGFR. However, surprisingly, the eGFR and TRV at one year of follow-up had a negative correlation. This finding contrasts with our current knowledge based on previous studies, which have shown that the loss of 50% of the renal mass after radical nephrectomy initiates compensatory mechanisms early in an attempt to alleviate the decrease in glomerular filtration rate. However, these mechanisms can be modified depending on age, tobacco consumption, obesity, hypoalbuminemia, the development of post-nephrectomy acute renal failure, which will ultimately determine the evolution of renal function and the risk of progression to CKD.<sup>17–19</sup>

Whether the compensation mechanisms after nephrectomy in the renal oncological context are different from those observed in other clinical situations remains to be elucidated. Thus, some studies have found a negative correlation between renal function and size of the tumor, especially in tumors larger than 5 cm.<sup>20,21</sup> In our cohort, the median tumor diameter was 6 cm, which may have influenced on the negative correlation of post-nephrectomy renal function.

The evolution of renal function after the loss of renal mass in the nephrectomized population behaves differently, depending on the etiology that determines the removal. In living kidney transplant donor patients, it appears that there is no significant loss of kidney function during follow-up,<sup>22</sup> whereas in nephrectomized patients for reasons other than donation, the results are variable. Nephrectomized patients for non-neoplastic causes maintain renal function many years after nephrectomy, especially in a young population with-

out major comorbidities. In contrast, other published series show worse results with progressive deterioration of renal function and development of proteinuria and progression to CKD.<sup>23</sup>

The TRV measured by the ellipsoid equation is an easy-to-use tool thanks to the availability of imaging tests (CT and/or MRI), being the most important biomarker that determine the evolution and prognosis of the function in patients with polycystic kidney disease.<sup>12,13</sup> Here, an inverse correlation is also observed between TRV and renal function over time. Although in these cases of polycystic kidney disease there is a clear explanation, due to the increase in cysts in number and volume with compression of the rest of the nephrons (decrease in renal mass) and interstitial fibrosis.

In this study we have tried to relate the volume of the remaining kidney before and after nephrectomy with renal function at one year of follow-up in a population with renal neoplasia.

Given the fact that serum Cr and eGFR may remain normal even with 50% kidney damage,<sup>24</sup> it is necessary to implement and search for new more sensitive markers capable to detect early which patients after radical nephrectomy for renal neoplasms are more susceptible to a poor evolution of kidney function and progression to CKD. Our results suggest that the measurement of TRV before and after nephrectomy in the remaining kidney could identify early those patients at risk of developing CKD, being probably a more significant parameter to consider when renal damage is subclinical, being useful as a possible biomarker that provides relevant information on the evolution of renal function in this group of patients.

This study has potential limitations:

1. First, due to the short follow-up, the long-term evolution of renal function cannot be determined, so a longer follow-up would be necessary to evaluate the natural course of renal function in this group of patients.
2. Second, the measurement of total renal volume with CT and/or renal MRI in a non-protocolized manner could have altered the results, associated with the measurement by a single observer that may cause an information bias.
3. Third, 24-h creatinine clearance was not available, which would have helped and provided more information with a better assessment and evolution of eGFR in this group of patients since the different formulas for measuring eGFR in this group of patients are not fully validated. The disadvantage of obtaining creatinine clearance is the difficulty in obtaining urine samples and the great variability of creatinine metabolism in various clinical settings.

Although this study has drawbacks and limitations, and only included a relatively small number of patients, it is a homogeneous series from a single center in a disease that is increasing, which helps to understand that the measurement of total renal volume before and after nephrectomy using the ellipsoid equation can represent a sensitive method to determine the early evolution of renal function and the compensatory capacity of the remaining kidney after radical nephrectomy for renal neoplasms.

## Conclusions

The conclusions generated from this study may be limited by its retrospective nature, however, they serve to demonstrate that the measurement of pre and post-nephrectomy TRV in the remaining kidney (year of follow-up) using the ellipsoid equation in nephrectomized patients due to renal neoplasms is strongly correlated with the evolution of the eGFR at one year of follow-up. These determinants may be useful to assess and monitor renal function and the compensatory capacity of the remaining kidney. Additional studies are necessary to determine the compensation mechanisms and prognostic factors of the population nephrectomized due to renal neoplasms.

## Key concepts

- Nephrectomies for renal neoplasms are a frequent cause of acute renal failure and chronic kidney disease, on the rise in recent years.
- The evolution and behavior of renal function in nephrectomized patients for renal neoplasms may be different from other non-neoplastic causes.
- Measurement of TRV in the remaining kidney in nephrectomized patients for renal neoplasms may be useful to assess the evolution of renal function.

## Conflict of interests

The authors declare that they have no conflict of interest related to the publication of this article.

## REFERENCES

1. Perazella MA, Dreicer R, Mitchell H. Renal cell carcinoma for the nephrologist. *Kidney Int.* 2018;94:471–83.
2. Cairns P. Renal cell carcinoma. *Cancer Biomark.* 2010;9:461–73.
3. Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. *Nephrol Dial Transplant.* 2015;30:1979–88.
4. Lowrance WT, Ordonez J, Udaltsova N, Russo P, Go S. CKD and the risk of incident cancer. *J Am Soc Nephrol.* 2014;25:2327–34.
5. Cho A, Lee JE, Kwon GY, Huh W, Lee HM, Kim YG, et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. *Nephrol Dial Transplant.* 2011;26:3496–501.
6. Schmid M, Krishna N, Ravi P, Meyer C, Becker A, Dalela D, et al. Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. *Urol Oncol.* 2016;34:293.e1–10.
7. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppe H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur Urol.* 2014;65:372–7.
8. Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, et al. Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. *Urology.* 2012;79:356–60.
9. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol.* 2006;7:735–40.
10. Schmid M, Abd-El-Barr AE, Gandaglia G, Sood A, Olugbade Jr K, Ruhotina N, et al. Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. *Urol Oncol.* 2014;32:1259–66.
11. Kim CS, Bae EH, Ma SK, Kweon SS, Kim SW. Impact of partial nephrectomy on kidney function in patients with renal cell carcinoma. *BMC Nephrol.* 2014;15:181.
12. Chapman AB, Bost JE, Torres VE, Woodford LG, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol.* 2012;7:479–86.
13. Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). *Kidney Int.* 2018;93:691–9.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40:373–83.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Chronic kidney disease epidemiology collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med.* 2006;145:247–54.
16. Kellum JA, Lameire N. Diagnosis, evaluation and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care.* 2013;17:204.
17. Barlow LJ, Korets R, Laudano M. Predicting renal function outcomes after surgery for renal cortical tumors: a multifactorial analysis. *BJU Int.* 2010;106:489–92.
18. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. *Int J Cancer.* 2005;114:101–8.
19. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the vitamin and lifestyle (VITAL) study. *J Urol.* 2013;190:1657–61.
20. Jeon HG, Choo SH, Sung HH, et al. Small tumor size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. *Eur J Cancer.* 2014;50:64–9.
21. Donin NM, Suh LK, Barlow L, Hruby GW, Newhouse J, McKiernan J. Tumor diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma. *BJU Int.* 2012;109:379–83.
22. Burballa C, Crespo M, Redondo-Pachón D, Pérez-Sáez MJ, Arias-Cabrales A, Mir M, et al. Factors associated with renal function compensation after donor nephrectomy. *Nefrologia.* 2018;38:528–34.

23. Malcolm JB, Bagrodia A, Derweesh IH, Mehrazin R, Diblasio CJ, Wake RW, et al. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. *BJU Int.* 2009;104:476–81.
24. Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. *Nephron Clin Pract.* 2014;127:94–100.